Phase 1 Study of Sorafenib in Combination with Bortezomib in Patients with Advanced Malignancies

BACKGROUND: Sorafenib (a VEGFR and multi-targeted kinase inhibitor) and Bortezomib (a proteasome inhibitor) have clinical antineoplastic activities as single agents, and combine synergistically in preclinical models. METHODS: This Phase I study was undertaken to define the toxicity and the maximum t...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Kumar, Shaji K., Jett, James, Marks, Randolph, Richardson, Ronald, Quevedo, Fernando, Moynihan, Timothy, Croghan, Gary, Markovic, Svetomir N., Bible, Keith C., Qin, Rui, Tan, Angelina, Molina, Julian, Kaufmann, Scott H., Erlichman, Charles, Adjei, Alex A.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: 2013
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3779429/
https://ncbi.nlm.nih.gov/pubmed/23887852
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-013-0004-2
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια